Allarity Acquisition Corp., sponsored by Allarity Therapeutics’ wholly owned subsidiary, is pursuing a proposed IPO with a $100 million base size and $115 million maximum if the over-allotment option is fully exercised. The transaction is expected to leave Allarity’s working-capital outlook unchanged through summer 2028.
Key Highlights
- Allarity Therapeutics said the proposed transaction does not change its expectation of sufficient working Capital through summer 2028.
- Allarity Acquisition Corp. has applied to list units on Nasdaq under ALLNU, with shares and warrants expected to trade separately under ALLN and ALLNW.
- Allarity Acquisition Corp. is pursuing a proposed initial public offering with a $100 million base size.
Allarity Acquisition Corp. sponsored by Allarity Therapeutics, Inc. (NASDAQ: ALLR), is pursuing a proposed initial public offering with a base size of $100 million. The offering could reach $115 million if underwriters exercise the over-allotment option in full.
Jesper Hoiland, a current Allarity board member and former executive vice president and president of Novo Nordisk, is expected to chair Allarity Acquisition Corp.’s board. The units have been proposed for Nasdaq listing under ALLNU.
Working Capital Outlook Remains Unchanged
Allarity Therapeutics said the proposed offering does not alter its expectation of having sufficient Working Capital to fund operations into summer 2028. The registration statement remains preliminary and subject to completion and has not become effective. Securities may not be sold, and offers to buy may not be accepted, before the registration statement becomes effective.
FAQs
Q: What is the proposed Allarity SPAC IPO size?
A: Allarity Acquisition Corp. is pursuing a proposed IPO with a $100 million base offering. The size could reach $115 million if the over-allotment option is fully exercised.
Q: What could the Allarity SPAC mean for ALLR funding?
A: Allarity Therapeutics said the proposed SPAC transaction does not change its expectation of sufficient working capital to fund operations into summer 2028.
Q: Who is expected to chair Allarity Acquisition Corp.’s board?
A: Jesper Hoiland is expected to chair the board. He is a current Allarity board member and former executive vice president and president of Novo Nordisk.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.